問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Radiation Therapy

Division of Urology

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

An Nan Hospital-China Medical Univeristy (在職)

更新時間：2023-09-19

林精湛Lin, Ching-Chan
  • Co-Principal Investigator
  • Clinical Trial Experience (year) -18 years -3 個月

  • linchin13256@yahoo.com.tw

Recruiting Trial

115Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林精湛

List

207Cases

2024-12-01 - 2028-08-18

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2024-12-01 - 2024-12-02

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2024-12-30 - 2031-06-26

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2026-06-01 - 2030-12-31

Phase III

Not yet recruiting
Multicenter, Phase III, Randomized, Placebo-controlled, Double-blind Study of Combination Therapy with D07001 Softgel Capsules and Capecitabine Versus Placebo and Capecitabine in Participants with Advanced Biliary Tract Cancer after Treatment Failure with Gemcitabine, Platinum, and FOLFOX or Irinotecan Regimens

  • Condition/Disease

    Biliary Tract Cancer (BTC)

  • Test Drug

    CAPECITABINE D07001-Softgel Capsules Placebo 艾結達膜衣錠 500 毫克 克癌特膜衣錠150毫克 克癌特膜衣錠500毫克 截瘤達錠５００毫克

Participate Sites
9Sites

Not yet recruiting9Sites

2026-08-28 - 2032-02-19

Phase III

Not yet recruiting
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY

  • Condition/Disease

    Urothelial Cancer, Urinary Bladder Neoplasms

  • Test Drug

    Enfortumab Vedotin Pembrolizumab

Participate Sites
6Sites

Not yet recruiting6Sites

2025-10-01 - 2029-12-31

Active
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Squamous Cell Carcinoma of Head and Neck

  • Test Drug

    注射劑 皮下注射劑 注射劑 注射劑 注射劑

Participate Sites
7Sites

Recruiting7Sites

2025-11-01 - 2030-12-31

Phase III

Active
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-engaging Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

  • Condition/Disease

    Prostatic Neoplasms, Castration-Resistant

  • Test Drug

    靜脈輸注液 靜脈輸注液 錠劑

Participate Sites
5Sites

Recruiting5Sites

2019-12-01 - 2030-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Not yet recruiting4Sites

Recruiting12Sites

2017-06-15 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated4Sites

林永昌
Linkou Chang Gung Medical Foundation

黃書彬
Kaohsiung Municipal Gangshan Hospital

未分科

2016-06-01 - 2024-06-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated6Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

1 2 3 4 5 21
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB